{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:27:42Z","timestamp":1770985662501,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.tranon.2024.102057","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T06:01:38Z","timestamp":1721282498000},"page":"102057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Potentially actionable targets in synovial sarcoma: A tissue microarray study"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-0688","authenticated-orcid":false,"given":"Lore","family":"De Cock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Paternostro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Vanleeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karo","family":"Wyns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-442X","authenticated-orcid":false,"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-5929","authenticated-orcid":false,"given":"Che-Jui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raf","family":"Sciot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2024.102057_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.tranon.2024.102057_bib0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.anndiagpath.2014.09.002","article-title":"Synovial sarcoma: defining features and diagnostic evolution","volume":"18","author":"Thway","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"issue":"15","key":"10.1016\/j.tranon.2024.102057_bib0003","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/cncr.24424","article-title":"Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients","volume":"115","author":"Sultan","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2024.102057_bib0004","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/COC.0000000000000148","article-title":"Effects of adjuvant radiotherapy in patients with synovial sarcoma","volume":"40","author":"Song","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2024.102057_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101618","article-title":"Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies","volume":"8","author":"Blay","year":"2023","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.tranon.2024.102057_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110417","article-title":"Systemic anti-cancer therapy in synovial sarcoma: a systematic review","volume":"10","author":"Riedel","year":"2018","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2024.102057_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6675260","article-title":"Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research","author":"Lee","year":"2021","journal-title":"Sarcoma"},{"issue":"2","key":"10.1016\/j.tranon.2024.102057_bib0008","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2024.102057_bib0009","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2024.102057_bib0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","article-title":"MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1","volume":"471","author":"Iura","year":"2017","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.tranon.2024.102057_bib0011","first-page":"3937","article-title":"Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma","volume":"17","author":"Kakimoto","year":"2019","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.tranon.2024.102057_bib0012","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4161\/onci.21059","article-title":"NY-ESO-1 expression in sarcomas: a diagnostic marker and immunotherapy target","volume":"1","author":"Lai","year":"2012","journal-title":"Oncoimmunology."},{"issue":"10435","key":"10.1016\/j.tranon.2024.102057_bib0013","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2024.102057_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0083-x","article-title":"Metastatic biomarkers in synovial sarcoma","author":"de Necochea-Campion","year":"2017","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0016","first-page":"783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic. Acids. Res."},{"issue":"5","key":"10.1016\/j.tranon.2024.102057_bib0017","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2024.102057_bib0018","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.tranon.2024.102057_bib0019","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102057_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/168145","article-title":"A pilot study of anti-CTLA4 antibody Ipilimumab in patients with synovial sarcoma","author":"Maki","year":"2013","journal-title":"Sarcoma"},{"key":"10.1016\/j.tranon.2024.102057_bib0021","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41305.044","article-title":"Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma","author":"Brien","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.tranon.2024.102057_bib0022","series-title":"Connective Tissue Oncology Society Annual Meeting","article-title":"Preclinical validation of target engagement assay and investigation of mechanistic impacts of FHD-609, a clinical-stage BD9 degrader being developed for the treatment of synovial sarcoma","author":"Collins","year":"2022"},{"issue":"12_Supplement","key":"10.1016\/j.tranon.2024.102057_bib0023","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-ND09","article-title":"Abstract ND09: the discovery and characterization of CFT8634: a potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers","volume":"82","author":"Jackson","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0024","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.tranon.2024.102057_bib0025","doi-asserted-by":"crossref","first-page":"30094","DOI":"10.18632\/oncotarget.8979","article-title":"TAZ and YAP are frequently activated oncoproteins in sarcomas","volume":"7","author":"Fullenkamp","year":"2016","journal-title":"Oncotarget."},{"issue":"12","key":"10.1016\/j.tranon.2024.102057_bib0026","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/1078-0432.CCR-17-3553","article-title":"SS18-SSX-dependent YAP\/TAZ signaling in synovial sarcoma","volume":"25","author":"Isfort","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56247-8","article-title":"Prevalence of the Hippo effectors YAP1\/TAZ in tumors of soft tissue and bone","volume":"9","author":"Isfort","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0028","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-014-0222-5","article-title":"Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?","volume":"10","author":"Palmerini","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"issue":"8","key":"10.1016\/j.tranon.2024.102057_bib0029","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ijc.24128","article-title":"Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma","volume":"124","author":"Oda","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2024.102057_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/593708","article-title":"The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma","author":"Kim","year":"2011","journal-title":"Sarcoma"},{"issue":"5","key":"10.1016\/j.tranon.2024.102057_bib0031","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/modpathol.3800587","article-title":"CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis","volume":"19","author":"Oda","year":"2006","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"Debnath","year":"2013","journal-title":"Theranostics."},{"issue":"3","key":"10.1016\/j.tranon.2024.102057_bib0033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10585-007-9133-3","article-title":"Inhibition of the CXCR4\/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases","volume":"25","author":"Kim","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.tranon.2024.102057_bib0034","article-title":"Abstract LB001: identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.tranon.2024.102057_bib0036","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/PAS.0000000000001447","article-title":"A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma","volume":"44","author":"Baranov","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.tranon.2024.102057_bib0037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2023.09.2923","article-title":"200P Precise tumor & patient selection for CDR404: a bispecific & bivalent MAGE-A4 T cell engager","volume":"34","author":"Giacomazzi","year":"2023","journal-title":"Annal. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2024.102057_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000101","article-title":"Expression of MAGE-A and NY-ESO-1 in primary and metastatic Cancers","volume":"39","author":"Park","year":"2016","journal-title":"J. ImmunOther"},{"issue":"14","key":"10.1016\/j.tranon.2024.102057_bib0039","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.18632\/oncotarget.2101","article-title":"NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma","volume":"5","author":"Giesen","year":"2014","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.tranon.2024.102057_bib0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.humpath.2013.05.029","article-title":"Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma","volume":"45","author":"Aung","year":"2014","journal-title":"Hum. Pathol."},{"issue":"20","key":"10.1016\/j.tranon.2024.102057_bib0041","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1158\/1078-0432.CCR-20-0832","article-title":"HLA genotyping in synovial sarcoma: identifying HLA-A*02 and its association with clinical outcome","volume":"26","author":"Rosenbaum","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2024.102057_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002072","article-title":"Targeting cancer testis antigens in synovial sarcoma","volume":"9","author":"Mitchell","year":"2021","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.tranon.2024.102057_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.tranon.2024.102057_bib0044","article-title":"Clinicopathological assessment of cancer\/testis antigens NY-ESO-1 and MAGE-A4 in highly aggressive soft tissue sarcomas","volume":"12","author":"Hashimoto","year":"2022","journal-title":"Diagnostics. (Basel)"},{"issue":"12","key":"10.1016\/j.tranon.2024.102057_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004069","article-title":"Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2","volume":"3","author":"Fischer","year":"2008","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.tranon.2024.102057_bib0046","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for pathologists: protocols, pitfalls, and tips","volume":"50","author":"Kim","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.tranon.2024.102057_bib0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.aanat.2019.03.013","article-title":"Influence of fixation method and duration of archiving on immunohistochemical staining intensity in embryonic and fetal tissues","volume":"224","author":"Tauber","year":"2019","journal-title":"Ann. Anat."},{"issue":"11","key":"10.1016\/j.tranon.2024.102057_bib0048","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/jclinpath-2017-204387","article-title":"Immunohistochemistry on old archival paraffin blocks: is there an expiry date?","volume":"70","author":"Grillo","year":"2017","journal-title":"J. Clin. Pathol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T21:49:02Z","timestamp":1723326542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"alternative-id":["S1936523324001840"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102057","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentially actionable targets in synovial sarcoma: A tissue microarray study","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102057"}}